5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.

Trial Profile

5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Nordic-VII
  • Most Recent Events

    • 01 Aug 2017 Results evaluating the effect of cetuximab on health-related quality of life (HRQoL) in the NORDIC-VII trial on metastatic colorectal cancer (mCRC), published in the European Journal of Cancer.
    • 11 Apr 2017 Results of final survival analyses and extended RAS data published in the British Journal of Cancer.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top